+

WO2018186706A1 - Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant - Google Patents

Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant Download PDF

Info

Publication number
WO2018186706A1
WO2018186706A1 PCT/KR2018/004043 KR2018004043W WO2018186706A1 WO 2018186706 A1 WO2018186706 A1 WO 2018186706A1 KR 2018004043 W KR2018004043 W KR 2018004043W WO 2018186706 A1 WO2018186706 A1 WO 2018186706A1
Authority
WO
WIPO (PCT)
Prior art keywords
natural killer
cancer
fusion polypeptide
cxcl16
cell
Prior art date
Application number
PCT/KR2018/004043
Other languages
English (en)
Korean (ko)
Inventor
김석호
이재민
조덕
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to JP2019554653A priority Critical patent/JP6933724B2/ja
Priority to US16/500,051 priority patent/US11655306B2/en
Priority to RU2019135054A priority patent/RU2740438C1/ru
Priority to IL269801A priority patent/IL269801B2/en
Priority to CA3057989A priority patent/CA3057989C/fr
Priority to CN201880025476.7A priority patent/CN110573529A/zh
Priority to MX2019011958A priority patent/MX2019011958A/es
Priority to AU2018248672A priority patent/AU2018248672B2/en
Priority to BR112019020909-3A priority patent/BR112019020909A2/pt
Priority to EP18781754.9A priority patent/EP3594242A4/fr
Publication of WO2018186706A1 publication Critical patent/WO2018186706A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Definitions

  • the present invention relates to a novel anti-cancer immune cell treatment using fusion proteins and natural killer cells for increasing cancer inflow of natural killer cells and maximizing antibody dependent cytotoxicity (ADCC).
  • ADCC antibody dependent cytotoxicity
  • the present invention also relates to methods of treating cancer with the fusion protein and various uses of the fusion protein.
  • Natural killer cells perform the function of removing host cells infected with tumor cells, bacteria, intracellular parasites or viruses without prior sensitization by antigen, rejecting inappropriate bone marrow transplantation, and T cells It acts on the first line of immune system defense mechanism in vivo, such as regulating immune response.
  • the immunological function of spontaneous killer cells is governed by the balance of the stimulatory signal that causes its killing function and the inhibitory signal that inhibits the killing function. Specifically, natural killer cells that receive strong activation signals attack and remove target cells, and natural killer cells that receive strong inactivation signals save target cells.
  • ADCC antibody-dependent cell cytoxicity
  • natural killing Natural Killing
  • Both ADCC and spontaneous killing require the activation of protein tyrosine kinase (PTK) and have in common that they are blocked by inactivation signals transmitted by inactivating receptors of spontaneous killer cells. Since the killing function of NK cells depends on the balance of activation and inactivation signals, natural killer cells can distinguish and remove normal host cells from infected or tumorized cells.
  • PTK protein tyrosine kinase
  • Natural killer cells can be classified according to the expression level of CD56, and CD56 dim natural killer cells are distributed over 90% in peripheral blood natural killer cells.
  • CD56 dim is known to have higher cytotoxicity than other CD56-expressing natural killer cells. It is known.
  • CD56 bright killer cells are known to have fewer numbers and lower cytotoxicity than CD56 dim killer cells.
  • CD56 bright natural killer cells have been reported not only to have high immunomodulatory function (IFN-gamma, TNF-alpha, etc.) but also to have high ADCC (antibody dependent cellular cytotoxicity) function ( The Journal of Immunology, 2011, 186: 6753-6761). ).
  • CD56 bright natural killer cells are expected to have a synergistic effect in the combined treatment of antibodies and cancer.
  • tumors can express unique proteins associated with their malignant phenotype or overexpress certain proteins in greater numbers than normal cells.
  • Expression of unique proteins on the surface of tumor cells provides an opportunity to diagnose and characterize the disease by probing the phenotypic identity and biochemical composition and activity of the tumor or to target tumor-associated antigens and new treatments for the tumor. Have them develop a method.
  • Antibodies that exhibit an antigen-antibody response specific for the tumor-associated antigens induce cancer cells by inducing various biological immune responses (antibody-dependent cellular cytotoxic activity (ADCC), complement-dependent cytotoxic activity (CDC), etc.). Since it is known to induce cell death by attack, antibodies and the like which are useful for the treatment of tumors have been developed, but research and development for enhancing the therapeutic efficacy thereof are insufficient.
  • ADCC antibody-dependent cellular cytotoxic activity
  • CDC complement-dependent cytotoxic activity
  • the present invention provides an antibody or fragment thereof that binds a tumor associated antigen
  • fusion polypeptides comprising natural killer cell inducing proteins of CXCL16.
  • the invention also provides a nucleic acid encoding the fusion polypeptide, a vector comprising the same or a host cell comprising the vector.
  • the invention also relates to an antibody or fragment thereof that binds to a tumor associated antigen
  • compositions for preventing or treating cancer including a fusion polypeptide comprising a natural killer cell-derived protein of CXCL16.
  • the invention also relates to an antibody or fragment thereof that binds to a tumor associated antigen
  • a fusion polypeptide comprising natural killer cell-derived protein of CXCL16, and a pharmaceutical composition for preventing or treating cancer, including natural killer cells (Natural killer cells, NK cells).
  • the invention also provides a composition comprising said fusion polypeptide for use in the treatment of cancer.
  • the invention also provides the use of said fusion polypeptide in the manufacture of a medicament for the treatment of cancer.
  • the invention also provides the use of said fusion polypeptide for the treatment of cancer.
  • the invention also provides a method of treating cancer by administering to a patient a pharmaceutically effective amount of a composition comprising said fusion polypeptide.
  • CXCR3 and CXCR6 are present on the surface of natural killer cells among receptors of active inducers expressed on natural killer cells. Confirmed that the overexpression of CXCL16 among its ligands is effective for the migration of natural killer cells, and then fusion proteins of CXCL16 and tumor-associated antigen-specific antibodies prepared by natural killer cell-induced cells and administered to them.
  • the present invention was completed by remarkably enhancing the induction into cancer and having a remarkable effect on the treatment of cancer.
  • tumor-associated antigen refers to an antigen that is specifically expressed on tumor cells that are not expressed in normal cells or overexpressed only in tumor cells as compared to normal cells, preferably on the surface of tumor cells. Refers to antigenic substances produced in cells.
  • Tumor-associated antigens that are specifically expressed in tumors include, but are not limited to, for example, 4-1BB (CD137), 5T4, AGS-5, AGS-16, Angiopoietin 2, CD19 (Cluster of Differentiation 19), B7.1 (CD80), B7.2 (CD86), B7DC, B7H1, B7H2, B7H3, BT-062, BTLA, CAIX, Carcinoembryonic Antigen, CTLA4, Crypto, ED- B, ErbB1, ErbB2, ErbB3, ErbB4, EGFL7, EpCAM, EphA2, EphA3, EphB2, FAP, Fibronectin, Folic Acid Receptor, Ganglioside GM3, GD2, Glucocorticoid-induced Tumor Necrosis Factor Receptor (GITR) gplOO, gpA33, GPNMB, ICOS, IGFIR, integrin ⁇ , integrin ⁇ , KIR, LAG-3, Lewis
  • antibody includes whole antibodies, antibody fragments possessing antigen recognition and binding capacity, monoclonal antibodies, polyclonal antibodies, and antibody analogs.
  • the antibody may be IgM, IgG (eg IgG1, IgG2, IgG3 or IgG4), IgD, IgA, or IgE.
  • antibody fragment refers to a molecule comprising a portion of an intact antibody, generally the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab ', F (ab') 2, and Fv fragments; Single domain antibodies.
  • Said “antibody or fragment thereof” may specifically or preferably bind to tumor cells, preferably tumor associated antigens that are specifically expressed in tumors as compared to non-tumor cells or normal cells.
  • the binding between two binding partners eg, specifically binding
  • "preferably binds" eg, an antibody and an antigen that is a binding partner thereof
  • single-chain Fv or “single-chain variable fragment” refers to an antibody in which the variable domains of the heavy and light chains of a conventional two-chain antibody combine to form one chain.
  • linker peptides are inserted between the two chains to allow for the creation of suitable folding and active binding sites.
  • the term “antibody that binds an antigen” refers to an antibody useful as a therapeutic agent in which the antibody targets the antigen by binding to the antigen with sufficient affinity.
  • linker refers to a peptide that connects a first molecule (eg, an antibody or fragment thereof to a tumor-associated antigen) to a second molecule (a natural killer cell-derived protein of CXCL16) through chemical bonding or the like. it means.
  • cancer refers to a pathological condition in humans characterized by unregulated cell proliferation. But not limited to, carcinoma, lymphoma, blastoma, and leukemia. More specific examples of cancers include, but are not limited to: lung cancer (small cell and non-small cell), breast cancer, prostate cancer, carcinoma, bladder cancer, gastric cancer, pancreatic cancer, liver cancer (hepatocellular), hepatoblastoma, colon cancer, squamous head squamous cancer Cell carcinoma, esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, mesothelioma, melanoma, sarcoma, osteosarcoma, liposarcoma, thyroid cancer, driftoma, acute myeloid leukemia (AML), and chronic myeloid leukemia ( CML).
  • lung cancer small cell and non-small cell
  • breast cancer breast cancer
  • prostate cancer carcinoma
  • bladder cancer gastric cancer
  • pancreatic cancer liver cancer (hepatocellular)
  • expression vector includes a nucleotide sequence encoding a molecule of interest that is operably linked to a promoter.
  • polypeptide As used herein, "polypeptide”, “peptide” and “protein” are used interchangeably and include references to polymers of amino acid residues. The terms apply to natural amino acid polymers as well as amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding natural amino acid. The terms also apply to those polymers containing conservative amino acid substitutions so that the protein remains functional.
  • host cell means a cell capable of supporting the replication or expression of the expression vector.
  • the host cell can be a prokaryotic cell, for example Escherichia coli, or a eukaryotic cell, for example a yeast, insect, amphibian or mammalian cell.
  • inhibiting with respect to tumor or cancer growth or progression may be used to determine the growth, spread, or metastasis of a patient's tumor or cancer to an amount measurable using any method known in the art. Refers to inhibiting.
  • the growth, progression or spread of a tumor or cancer is about 10% relative to the tumor size prior to co-administration of the natural killer cells, eg, with fusion polypeptides of the invention and immune cell therapeutics, or prior to administration of the fusion polypeptide. If it decreases by more than 20%, 30%, 50%, 80% or 100%, it is suppressed, reduced or reduced.
  • the present invention provides an antibody or fragment thereof that binds a tumor associated antigen; Linker; And it provides a fusion polypeptide comprising a natural killer cell-derived protein of CXCL16.
  • the fusion polypeptide according to the present invention may specifically bind to the cell surface of a tumor, including an antibody or a fragment thereof, which binds to a tumor-associated antigen, and binds CXCL16, a natural killer cell-derived protein that is cleaved and released after antigen-antibody binding. Through natural killer cells can be induced to the desired tumor cells.
  • Tumor target surface antigens include antibodies or fragments thereof that specifically bind to tumor associated antigens.
  • Tumor target surface antigens are well known in the art and include, for example, mesothelin, PD-L1, Her2, CD19, MUC1, EGFR, VEGFR, B7H1, B7H2, B7H3, BT-062, BTLA, CAIX, 4-1BB, 5T4 , AGS-5 or AGS-16, but is not limited thereto.
  • Antibodies or fragments thereof that specifically bind to the tumor associated antigen include single chain Fv (scFv), Fab, Fab ', F (ab') 2, disulfide stabilized antibodies, and the like, and specifically, single chain Fv ( scFv).
  • Preparation of the antibody or fragment thereof that specifically binds to the tumor associated antigen may be prepared according to known production methods in the art.
  • said antibody is a single chain Fv (scFv).
  • the V H and V L regions of the scFv antibody include single chains that are folded to produce antigen binding sites similar to those found in double chain antibodies. Once folded, non-covalent interactions stabilize the single chain antibody.
  • the scFv is produced by recombination.
  • Conservative variants of the antibodies of the invention can be prepared conventionally, and conservative variants used in scFv fragments will retain important amino acid residues necessary for accurate folding and stabilization between the V H and V L regions.
  • scFv has an amino acid sequence represented by SEQ ID NO: 1 as the scFV of mesothelin, specifically, may be encoded by the nucleotide sequence represented by SEQ ID NO: 2.
  • scFV is a scFV of PD-L1, the heavy chain (V H ) encoded by the amino acid sequence represented by SEQ ID NO: 3, specifically, the nucleotide sequence represented by SEQ ID NO: 4; And a light chain (V L ) encoded by an amino acid sequence represented by SEQ ID NO: 5, specifically, a nucleotide sequence represented by SEQ ID NO: 6, wherein the tumor-associated antigen PD-L1 is a base represented by SEQ ID NO: 7 It may be encoded by the sequence, but is not limited thereto.
  • scFV is a scFV of Her2 is a heavy chain encoded by the amino acid sequence represented by SEQ ID NO: 8, specifically the nucleotide sequence represented by SEQ ID NO: 9; It may include a light chain encoded by the amino acid sequence represented by SEQ ID NO: 10, specifically, the nucleotide sequence represented by SEQ ID NO: 11, wherein the tumor-associated antigen Her2 is to be encoded by the nucleotide sequence represented by SEQ ID NO: 12 May be, but is not limited thereto.
  • scFV is a scFV of CD19 heavy chain encoded by the amino acid sequence represented by SEQ ID NO: 28, specifically, the nucleotide sequence represented by SEQ ID NO: 29; And a light chain encoded by an amino acid sequence represented by SEQ ID NO: 30, specifically, a nucleotide sequence represented by SEQ ID NO: 31, but is not limited thereto.
  • scFV is a scFV of MUC-1 is a heavy chain encoded by the amino acid sequence represented by SEQ ID NO: 32, specifically the nucleotide sequence represented by SEQ ID NO: 33; And a light chain encoded by an amino acid sequence represented by SEQ ID NO: 34, specifically, a nucleotide sequence represented by SEQ ID NO: 35, but is not limited thereto.
  • scFV is a scFV of EGFR is a heavy chain encoded by the amino acid sequence represented by SEQ ID NO: 36, specifically, the nucleotide sequence represented by SEQ ID NO: 37; And a light chain encoded by an amino acid sequence represented by SEQ ID NO: 38, specifically, a nucleotide sequence represented by SEQ ID NO: 39, but is not limited thereto.
  • scFV is a scFV of VEGFR is a heavy chain encoded by the amino acid sequence represented by SEQ ID NO: 40, specifically, the nucleotide sequence represented by SEQ ID NO: 41; And a light chain encoded by an amino acid sequence represented by SEQ ID NO: 42, specifically, a nucleotide sequence represented by SEQ ID NO: 43, but is not limited thereto.
  • the scFv antibody may be directly bound to the peptide linker through the light chain and may be bound through the Fc region to which the scFv is bound.
  • the Fc may have an amino acid sequence of SEQ ID NO: 13, specifically, may be encoded by a nucleotide sequence represented by SEQ ID NO: 14, but is not limited thereto.
  • the linker according to the present invention will not have any biological activity other than to bind the regions with a peptide linker or to preserve some minimum distance or other spatial relationship between them, but the constituent amino acids may not have any properties, e.g. It may be chosen to affect folding, net charge, or hydrophobicity.
  • the linker may comprise a cleavage sequence such that CXCL16 is isolated after the antibody binds to a tumor associated antigen.
  • Antibodies or fragments thereof that specifically bind to a tumor associated antigen may be up to 50 amino acids, typically up to 40 amino acids, preferably up to 30 amino acids, and more preferably up to 20 amino acids in length, even more preferred. May be linked via a peptide linker having 1 to 10 amino acids in length.
  • the peptide linker may comprise a sequence that is cleaved by any protease, and specifically, may be a peptide linker that includes consecutive amino acid residues of RVKR that are cleaved by purine, but is not limited thereto.
  • the fusion polypeptide according to the invention induces natural killer cells, including a purine cleavage site which is cleaved by the purine, ie, a purine cleavage site comprising a continuous amino acid residue which can be cleaved by the purine. Allow proteins to be released from cancer cells.
  • the purine cleavage site can be any polypeptide site cleavable by purine. As reported by Duckert et al. (Duckert et al., Protein Engineering, Design & Selection 17 (1): 107-112 (2004), the entire contents of which are incorporated herein by reference). Purine is an enzyme of the "evolutionary conserved dibasic- and monobasic-specific CA 2+ -dependent serine protease family" called substilisin / myxin-like proprotein convertase.
  • Purine cleavage site sequences known in the literature and the like are included herein, and specifically, may have an amino acid sequence of SEQ ID NO: 15, and may be encoded by a nucleotide sequence represented by SEQ ID NO: 16, but is not limited thereto.
  • the antibody or fragment thereof that binds the tumor associated antigen may be bound to the purine cleavage sequence via a purine cleavage site amino terminus and may directly bind to the heavy, light, Fc (constant region) or framework regions of the antibody. have.
  • the fusion protein of the present invention may induce spontaneous killer cells into tumor cells having antibodies associated with tumor-associated antigens, including the killer cell-derived proteins of CXCL16.
  • Natural killer cell-derived protein refers to a protein that induces natural killer cell influx into tumor cells, that is, a protein that can migrate natural killer cells to cancer cells with chemokine (chemokine).
  • the CXCL16 may have an amino acid sequence of SEQ ID NO.
  • CXCL16 may be encoded by the nucleotide sequence of SEQ ID NO: 18.
  • the natural killer cell-derived protein may be linked to an antibody or fragment thereof through a peptide linker.
  • the linker according to the present invention will not have any biological activity other than to bind the regions with a peptide linker or to preserve some minimum distance or other spatial relationship between them, but the constituent amino acids may not have any properties, e.g. It may be chosen to affect folding, net charge, or hydrophobicity.
  • the linker may also comprise a cleavage sequence by a cleavage sequence, such as any protease, such that CXCL16 is isolated after the antibody binds to a tumor associated antigen.
  • the peptide linker comprises a purine cleavage site which is cleaved by purine, ie a purine cleavage site comprising a contiguous amino acid residue which can be cleaved by purine.
  • Fusion polypeptides according to the present invention may be prepared via non-recombinant or recombinant methods known in the art, and preferably may be prepared via recombinant methods.
  • an antibody or fragment thereof that binds the tumor associated antigen; Linker; And expression vectors can be prepared by inserting into the vector a cDNA encoding the CNKCL16 natural killer cell-derived protein.
  • a base sequence comprising mesothelin scFv and Fc is inserted into a vector, specifically a pcDNA3.1 vector, and the base sequence encoding the purine cleavage site and natural killer cell-derived protein is immunoglobulin (
  • An expression vector is prepared by inserting it after the immunoglobulin sequence. Examples of the prepared expression vector is as described in Figure 2 below.
  • the prepared expression vector can be expressed in bacteria, plants, yeasts, insects and mammalian cells.
  • fusion polypeptides may be employed using a number of expression systems that can be used for protein expression, including Escherichia coli, other bacterial hosts, yeasts and various higher eukaryotic cells such as COS, CHO, HeLa and myeloma cell lines. It can manufacture.
  • the expression vector may be transfected into CHO cells from which purine has been removed to prepare a fusion polypeptide.
  • the fusion polypeptides prepared can be purified according to standard procedures in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, and the like, to provide the desired fusion polypeptides.
  • the present invention provides nucleic acids encoding fusion polypeptides.
  • the present invention provides an expression vector comprising a nucleic acid sequence encoding the fusion polypeptide.
  • an expression vector having the structure shown in FIG. 2 may be provided, and may have a nucleotide sequence of SEQ ID NO: 19.
  • the present invention provides a host cell comprising the expression vector.
  • the cells may be any one selected from COS, CHO, HeLa, and myeloma cell lines, but are not limited thereto.
  • the present invention provides an antibody or fragment thereof that binds a tumor associated antigen
  • Linker provides a pharmaceutical composition for preventing or treating cancer comprising a fusion polypeptide comprising a natural killer cell-derived protein of CXCL16.
  • the pharmaceutical composition for preventing or treating cancer according to the present invention is an immune cell therapy, specifically, has a remarkable effect on cancer prevention or treatment through induction of natural killer cells into cancer.
  • the pharmaceutical composition for preventing or treating cancer according to the present invention includes not only a direct therapeutic effect but also an action as an anticancer adjuvant.
  • the pharmaceutical composition of the present invention is effective for preventing or treating cancer.
  • the invention also relates to an antibody or fragment thereof that binds to a tumor associated antigen; Linker; And a fusion polypeptide comprising a natural killer cell inducing protein of CXCL16, and a natural killer cell.
  • the natural killer cell and the fusion polypeptide which are immune cell therapeutic agents, have a significant effect on preventing or treating cancer by greatly enhancing the influx of natural killer cells into cancer upon co-administration.
  • compositions for use in the present invention may be formulated by standard techniques using one or more physiologically acceptable carriers or excipients.
  • suitable pharmaceutical carriers are disclosed in the present invention and in Remington: The Science and Practice of Pharmacy, 21st Ed., University of the Sciences in Philadelphia, Lippencott Williams & Wilkins (2005).
  • the fusion polypeptides and / or killer cells of the invention may be formulated for administration by any suitable route, for example by inhalation, topically, nasal, oral, parenteral or rectal.
  • administration of the above-mentioned pharmaceutical compositions may be administered intradermal, subcutaneous, intravenous, intramuscular, intranasal, by inhalation, in the cerebral, intratracheal, intraarterial, intraperitoneal, in the bladder, in the pleura, in the coronary artery, subcutaneously or By intratumoral injection, it can be done using a syringe or other device.
  • Transdermal administration is also contemplated as inhalation or aerosol administration. Tablets and capsules can be administered orally, rectally or vaginally.
  • the pharmaceutical composition will typically comprise a fusion polypeptide, or a fusion polypeptide and natural killer cells, dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. Fusion polypeptides and natural killer cells may be provided together or separately.
  • a pharmaceutically acceptable carrier preferably an aqueous carrier.
  • Fusion polypeptides and natural killer cells may be provided together or separately.
  • Various aqueous carriers can be used, such as buffered saline and the like. These solutions are bactericidal and are generally free of undesirable substances.
  • These compositions can be sterilized by conventional, well known sterilization techniques.
  • the compositions may be used as pharmaceutically acceptable auxiliary substances as required to approach physiological conditions, such as pH adjusting and buffering agents, toxicity modifiers and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. It may contain.
  • concentration of fusion polypeptides in these formulations can vary widely and will be selected based primarily on
  • compositions of the present invention are suitable for parenteral administration, including intravenous or intracavitary administration.
  • the fusion polypeptides and / or killer cells of the invention can be formulated for parenteral administration by injection, eg, by bolus injection or continuous infusion.
  • Injectable formulations may be present in unit dosage form, eg, in ampoules or in multiple-dose containers, with a preservative added.
  • Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are preferably prepared from fatty emulsions or suspensions.
  • the composition may be sterilized and / or the composition may contain auxiliaries such as preservatives, stabilizers, wetting or emulsifiers, dissolution accelerators, osmotic pressure regulating salts and / or buffers.
  • the active ingredient may be present in powder form, which is constituted by water without a suitable vehicle, eg, sterile pyrogen, before use.
  • the active ingredient may also contain other therapeutically valuable substances.
  • the compositions are prepared according to each conventional mixing, granulation or coating method, which contains about 0.1 to 75%, preferably about 1 to 50% of the active ingredient.
  • the pharmaceutical compositions or medicaments may be in the form of tablets or capsules, eg prepared by conventional means, together with pharmaceutically acceptable excipients.
  • the active ingredient i.e. the composition of the present invention, may be prepared by (a) diluents or fillers, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose (e.g.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and / or hydroxypropyl methylcellulose;
  • disintegrants for example starch (eg potato starch or sodium starch), glycolate, agar, alginic acid or its sodium salt, or effervescent mixtures; Preference is given to tablets and gelatin capsules comprising (e) wetting agents such as sodium lauryl sulfate and
  • the present invention administers a pharmaceutical composition to a patient in a therapeutically effective dose for preventing, treating or inhibiting a disease such as cancer or a malignant condition thereof.
  • the pharmaceutical composition is administered to the patient in an amount sufficient to elicit an effective therapeutic or diagnostic response in the patient.
  • An effective therapeutic or diagnostic response is one that at least partially arrests or slows down the symptoms or complications of the disease or malignant condition.
  • a suitable amount to accomplish this is defined as a "therapeutically effective amount.”
  • the dosage of the fusion polypeptide and / or natural killer cells to be administered depends on the species, weight, age, individual condition of the mammal, the surface area of the area to be treated and the dosage form.
  • the size of the dose will also be determined by the presence, nature and extent of any side effects that accompany the administration of the particular compound in the particular patient.
  • a unit dosage for administration to a mammal, preferably a human, of about 50 to 80 kg may contain an amount of about 1 mg / kg to 5 mg / kg for the fusion polypeptide and about 1 x for natural killer cells. It may contain an amount of 10 5 cells / kg to 2 x 10 7 cells / kg.
  • the dosage of the composition of the invention is a dosage sufficient to achieve the desired effect.
  • Optimal dosing schedules can be calculated from measurements of fusion polypeptides and / or killer cells, accumulation in the patient's body. It may be given more than once a day, week, month or yearly. Those skilled in the art can readily determine the optimum dosage, method of administration and repetition rate. Those skilled in the art will be able to determine optimal administration for administration of fusion polypeptides and / or killer cells to humans according to established protocols known in the art and disclosed herein.
  • the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the severity of the disease, the route of administration, the patient's weight, age and gender, and therefore the dosage should be determined in some respects. It does not limit the scope of the present invention.
  • the invention also provides a composition comprising said fusion polypeptide for use in the treatment of cancer.
  • the invention also provides the use of said fusion polypeptide in the manufacture of a medicament for the treatment of cancer.
  • the invention also provides the use of said fusion polypeptide for the treatment of cancer.
  • the invention also provides a method of treating cancer by administering to a patient a pharmaceutically effective amount of a composition comprising said fusion polypeptide.
  • the method of treating cancer may be administered with natural killer cells, thereby exhibiting an elevated therapeutic effect.
  • Fusion proteins for preventing or treating cancer of the present invention include antibodies or fragments thereof that bind to tumor associated antigens; Linker; And a fusion polypeptide comprising a natural killer cell-derived protein of CXCL16, thereby significantly enhancing the influx of natural killer cells into cancers expressing specific antigens when co-administered with natural killer cells, which are immunocytotherapeutic agents. Significant effect on treatment.
  • Figure 1 shows the results confirmed the degree of migration of Expanded natural killer cells according to chemokine type.
  • FIG. 2 shows a schematic diagram of an expression vector for producing a fusion polypeptide according to the present invention.
  • Figure 3 shows the result of confirming that the fusion polypeptide prepared according to the invention recognizes and binds mesothelin present on the surface of the pancreatic cancer cell line by the mesothelin recognition site.
  • FIG. 4 shows the results of confirming that the fusion polypeptide prepared according to the present invention recognizes and binds PD-L1 present on the surface of the pancreatic cancer cell line by the PD-L1 recognition site.
  • FIG. 5 shows the results of confirming that the fusion polypeptide prepared according to the present invention recognizes and binds Her2 present on the surface of the pancreatic cancer cell line by Her2 recognition site.
  • Figure 6 is a diagram showing the results confirming that the fusion polypeptide prepared according to the present invention binds to the pancreatic cancer cell line to release CXCL16.
  • Figure 7 is a view showing the results confirmed that the mobility of natural killer cells increased according to the treatment of various cancer cell lines fusion polypeptide of the present invention comprising an antibody binding to mesothelin.
  • FIG. 8 is a diagram showing the results of confirming that the influx of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising the antibody binding to PD-L1 to the Panc-1 cell line.
  • FIG. 9 is a view showing the results of confirming that the influx of natural killer cells increased according to the treatment of the fusion polypeptide of the present invention comprising an antibody binding to PD-L1 to the HT-29 cell line.
  • FIG. 10 is a diagram showing the results of confirming that the influx of natural killer cells increased by treating the Panc-1 cell line with the fusion polypeptide of the present invention including the antibody binding to Her2.
  • FIG. 11 is a diagram showing the results of confirming that the influx of natural killer cells increased by treating the MCF7 cell line with the fusion polypeptide of the present invention including the antibody binding to Her2.
  • FIG. 12 is a diagram showing the results of confirming that the mobility of natural killer cells increased according to the treatment of various cancer cell lines with the fusion polypeptide of the present invention comprising an antibody binding to CD19.
  • FIG. 13 is a diagram showing the results of confirming that the mobility of natural killer cells increased according to the treatment of various cancer cell lines with the fusion polypeptide of the present invention including the antibody binding to MUC-1.
  • FIG. 13 is a diagram showing the results of confirming that the mobility of natural killer cells increased according to the treatment of various cancer cell lines with the fusion polypeptide of the present invention including the antibody binding to MUC-1.
  • FIG. 14 is a diagram showing the results confirming that the mobility of natural killer cells increased according to treatment of various fusion polypeptides of the present invention comprising an antibody binding to EGFR in various cancer cell lines.
  • 15 is a diagram showing the results confirming that the mobility of natural killer cells increased according to treatment of various fusion polypeptides of the present invention including antibodies that bind VEGFR to various cancer cell lines.
  • Figure 16 shows the results confirming that the infiltration capacity of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising an antibody that binds mesothelin to various cancer cell lines.
  • FIG. 17 is a diagram showing the results of confirming that the invasive ability of natural killer cells was increased by treating the Panc-1 cell line with the fusion polypeptide of the present invention containing the antibody binding to PD-L1.
  • FIG. 17 is a diagram showing the results of confirming that the invasive ability of natural killer cells was increased by treating the Panc-1 cell line with the fusion polypeptide of the present invention containing the antibody binding to PD-L1.
  • FIG. 18 is a diagram showing the results of confirming that the invasiveness of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising the antibody binding to PD-L1 to the HT-29 cell line.
  • FIG. 18 is a diagram showing the results of confirming that the invasiveness of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising the antibody binding to PD-L1 to the HT-29 cell line.
  • FIG. 19 is a diagram showing the result of confirming that the invasive ability of natural killer cells increased by treatment of the fusion polypeptide of the present invention containing the antibody binding to Her2 in Panc-1 cell line.
  • 20 is a diagram showing the results of confirming that the infiltration capacity of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising an antibody binding to Her2 to MCF7 cell line.
  • Figure 21 is a diagram showing the results confirmed that the infiltration capacity of natural killer cells increased by treatment of the fusion polypeptide of the present invention containing an antibody that binds CD19 to various cancer cell lines.
  • Figure 22 shows the results confirming that the infiltration capacity of natural killer cells increased by treatment of various fusion polypeptides of the present invention comprising an antibody that binds to MUC-1 to various cancer cell lines.
  • Figure 23 is a view showing the results confirmed that the infiltration capacity of natural killer cells increased by treatment of the fusion polypeptide of the present invention containing an antibody that binds to EGFR in various cancer cell lines.
  • Figure 24 shows the results confirming that the infiltration capacity of natural killer cells increased by treatment of the fusion polypeptide of the present invention comprising an antibody binding to VEGFR to various cancer cell lines.
  • 25 is a view showing the results confirmed that the infiltration capacity of natural killer cells increased by the fusion polypeptide (Her2 scFv NRP-body) prepared to recognize Her2 according to the present invention.
  • Figure 26 is a diagram showing the induction of natural killer cells to cancer tissues following administration of the fusion polypeptide and natural killer cells prepared according to the present invention.
  • Figure 27 is a diagram showing the result of confirming the therapeutic effect by administering the mesothelin scFv fusion polypeptide prepared according to the present invention with natural killer cells in a pancreatic cancer transplant animal model.
  • Figure 28 is a diagram showing the result of confirming the therapeutic effect by administering the PD-L1 scFv fusion polypeptide prepared according to the present invention with natural killer cells in a pancreatic cancer transplant animal model.
  • 29 is a diagram showing the result of confirming the therapeutic effect by administering the Her2 scFv fusion polypeptide prepared according to the present invention with natural killer cells in a pancreatic cancer transplant animal model.
  • FIG. 30 is a diagram showing the distribution of natural killer cells when CXCL16 and IL-2 are treated in natural killer cells for a short time.
  • FIG. 31 is a diagram showing the distribution of natural killer cells when CXCL16 and IL-2 are treated in natural killer cells for a long time.
  • FIG. 32 shows CD56 bright distributed in the treatment of fusion polypeptides prepared according to the present invention in NK cells.
  • Fig. 3 shows the results of confirming that cell death is enhanced by CD16 + natural killer cells.
  • expanded NK cells were recovered and centrifuged at 1,500 rpm. Then, the supernatant was removed and the cells were counted after washing with PBS. CXCL9, CXCL10, CXCL11, and CXCL16 were each dispensed with chemokine at the bottom layer of the boyden chamber plate, and 2 x 10 5 cells of Expanded NK cells were dispensed at the upper layer of the boyden chamber plate. Then, incubated for 2 hours in a CO 2 incubator at 37 °C, the bottom layer was recovered, centrifuged at 1,500 rpm.
  • CD56-PE staining was performed at 4 ° C. for 30 minutes and washed with PBS.
  • Count Bright Absolute Counting Beads (Invitrogen) were dispensed by 50 ul for FAC analysis and FACS analysis was performed.
  • CXCL16 showed a significant effect on the migration of Expanded natural killer cells in comparison with other chemokines.
  • a recombinant vector was prepared in which a scFv sequence that recognizes a cancer target antigen, a purine sequence that acts as a linker, and CXCL16 (NK cell Recruitment Protein; NRP), which induce the influx of natural killer cells with the highest efficiency, were prepared.
  • FIG. 2 The structure of a specific recombinant vector to which a scFv sequence that recognizes mesothelin as a target antigen is bound is shown in FIG. 2.
  • the pcDNA3.1 vector was digested with Sfi1 enzyme for 2 hours and purified to prepare a ligation vector.
  • amplification was carried out by PCR based on the primer sequences shown in Table 1 below to obtain the mesothelin scFv base sequence of SEQ ID NO: 2, and the mixture of the vector and the insert sample and the T4 ligase was mixed for 2 hours at 25 ° C. Ligation of the vector and the insert was performed by incubation. This was inserted into the Sfi1 enzyme site of the pcDNA3.1 vector.
  • amplification was carried out by PCR based on the primer sequences shown in Table 2 below to obtain a PD-L1 scFv base sequence comprising the heavy chain of SEQ ID NO: 4 and the light chain of SEQ ID NO: 6, wherein the mesothelin
  • the ligation of the vector and the insert was performed in the same manner as the method for preparing the scFv-coupled vector, which was inserted into the Sfi1 enzyme site of the pcDNA3.1 vector.
  • PD-L1 scFv Manufacturing primer order order PD-L1 scFv Forward primer 5'-GGCCCAGCCGGCCATGCAGGTCCAAC TTGTGCAGTC-3 '(SEQ ID NO: 22)
  • Her2 scFv amplification was carried out by PCR based on the primer sequences shown in Table 3 below to obtain a Her2 scFv sequence including the heavy chain of SEQ ID NO: 9 and the light chain of SEQ ID NO: 11, wherein the mesothelin scFv was bound.
  • the ligation of the vector and the insert was performed in the same manner as the preparation method of the vector, and it was inserted into the Sfi1 enzyme site of the pcDNA3.1 vector.
  • the base sequence for the scFv (CD19 scFv comprising the heavy chain of SEQ ID NO: 29 and the light chain of SEQ ID NO: 31; SEQ ID NO: 33 based on the amino acid sequence of each scFv to prepare CD19, MUC-1, EFGR and VEGFR scFv) MUC-1 scFv comprising a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 35; EGFR scFv comprising a heavy chain of SEQ ID NO: 37 and a light chain of SEQ ID NO: 39; VEGFR scFv comprising a heavy chain of SEQ ID NO: 41 and a light chain of SEQ ID NO: 43)
  • the ligation of the vector and the insert was performed in the same manner as the method for preparing the mesothelin scFv-coupled vector, and inserted into the Sfi1 enzyme site of the pcDNA3.1 vector.
  • the CXCL16 and purine cleavage sites were amplified by PCR based on the primer sequences shown in Table 4 below to use immunoglobulins present in the vector and then the Not1 enzyme site.
  • the scFV-inserted vector that recognizes the target antigen was digested with Not1 enzyme for 2 hours and purified, and then the vector and the insert CXCL16 sample were mixed with ligase enzyme and incubated at 25 ° C for 2 hours to perform ligation of the vector and the insert. .
  • the produced expression vector was transformed into CHO (Chinese hamster ovary) cells from which purine was removed to mass produce fusion polypeptides (NRP-body).
  • CHO cells transfected with the expression vector were cultured in a 150 mm plate, and recovered by incubating for 72 hours in a roller bottle incubator. The recovered culture solution was centrifuged and only the supernatant was purified using a protein A-agarose column of the AKTA Protein Purification System (GE Healthcare Life Sciences) to produce a fusion polypeptide.
  • Example 2 Mesothlin scFV NRP-body (0.1-2 ⁇ g / ml) prepared in Example 2 was dispensed on 2 ⁇ 10 5 panc-1 cells, a pancreatic cancer cell line, and incubated at 4 ° C. for 20 minutes. . Cells were then recovered, washed with PBS, and FITC-bound FC antibody (1 ⁇ g / ml) was aliquoted and incubated at 4 ° C. for 20 minutes. Then, after collecting the cells again, the cells were washed with PBS and analyzed by FACS.
  • PD-L1 scFv NRP-body and Her2 scFv NRP-body recognize PD-L1 or Her2 present on the surface of pancreatic cancer cell line through antigen recognition sites, respectively. It was confirmed that the binding specifically, through this it was confirmed that the fusion polypeptide of the present invention can be applied to the antibody that specifically binds to the target antigen according to the target tumor-associated antigen.
  • CXCL16 ELISA was performed according to the method of Human CXCL16 ELISA kit (# DCX160) of the R & D system.
  • a mesothelin scFV fusion polypeptide (Mesothlin scFV NRP-body) was dispensed into a 96-well ELISA plate (R & D) at 0.5 ⁇ g / mL and 50 ⁇ l / Well, and allowed to stand at room temperature for 2 hours for adsorption. . After washing the plate, 200 ⁇ l / well of peroxidase label was added as a secondary antibody and left at room temperature for 2 hours. The plate was washed with Tween-PBS, then ABTS substrate solution was added and developed to measure absorbance at 415 nm using a plate reader.
  • fusion polypeptide (NRP-body) was bound to the mesothelin of the pancreatic cancer cell line Panc-1 and CXCL16 was released as the purine cleavage site of the fusion polypeptide was cleaved by the purine of the cancer cells.
  • Example 2 After the fusion polypeptide prepared in Example 2 recognizes and binds to a cancer expressing a target antigen, it was confirmed by using a Boyden cahamber system that natural killer cell influx was increased by releasing CXCL16, a natural killer cell induction-inducing protein.
  • Natural killer cells were labeled with CFSE (BioLegend, #RUO 423801), aliquoted at 2 ⁇ 10 5 in the upper layer, and incubated for 4 hours at 37 ° C. in a CO 2 incubator. Then, bottom layer cells were recovered and the distribution of CFSE-labling natural killer cells was confirmed through FACS.
  • CFSE BioLegend, #RUO 423801
  • the PD-L1 scFv-fusion polypeptide and Her2 scFv-fusion polypeptide prepared in Example 2 were dispensed into a Panc-1, HT-29 or MCF7 cell line and subjected to Boyden cahamber under the same conditions as the mesothelin scFv-fusion polypeptide experiment.
  • the inflow of natural killer cells was confirmed through the system, and the results are shown in FIG. 8 (PD-L1 scFV NRP-body for Pan-1), FIG. 9 (PD-L1 NRP-body for HT-29), and FIG. 10 (Her2 NRP-body for Pan-1) and FIG. 11 (Her2 scFV NRP-body for MCF7).
  • the CD-19, MUC-1, EGFR and VEGFR scFv-fusion polypeptide prepared in Example 2 was HPDE, K562 (ATCC, Cat.CCL-243), HCT116 (ATCC, Cat.CCL-247), Panc
  • the cell lines were divided into -1 (ATCC, Cat.CRL-1469) or MCF7 (ATCC, Cat.HTB-22) cell lines to confirm the influx of natural killer cells through the Boyden cahamber system under the same conditions as the mesothelin scFv experiment.
  • the results are shown in FIG. 12 (CD19 scFV NRP-body), FIG. 13 (MUC-1 scFV NRP-body), FIG. 14 (EGFR scFV NRP-body), and FIG. 15 (VEGFR scFV NRP-body).
  • HPDE, Panc-1, HCT116, MCF7, HT-29 and K562 cell lines 2 ⁇ 10 5 to the bottom layer of the Boyden Chamber assay plate (Fisher Scientific, # 07-200-155) after 37 ° C, CO
  • the cells were incubated for 2 hours in two incubators, and 1 ⁇ g / ml of the fusion polypeptide prepared in Example 2 was dispensed into each cell line.
  • matrigel BD, # 354234
  • the natural killer cells were divided into 2 x 10 5 and incubated for 48 hours in 37 °C, CO 2 incubator. Thereafter, the upper layer was recovered, stained with crystal violet for 1 hour, and then randomly photographed three portions of the upper layer, and the invasive ability of natural killer cells was measured by image J program.
  • Results for each fusion polypeptide are shown in FIGS. 16-24, respectively.
  • ADCC Antibody Dependent Cellular Cytotoxicity
  • Panc-1 cell lines were dispensed into 96-well plates and incubated for 2 hours at 37 ° C. in a CO 2 incubator.
  • 1 ⁇ g / ml of mesothelin scFV-fusion polypeptide was treated in a target cell and then incubated at 37 ° C. in a CO 2 incubator for 2 hours.
  • Natural killer cells were added as 2 x 10 5 so that the ratio of the target cell and the effector cell was 1: 1, and the cells were incubated for 4 hours at 37 °C, CO 2 incubator.
  • Cells were harvested, washed with PBS, stained with Annexin V (1 ⁇ g / ml) and PI (1 ⁇ g / ml) for 30 minutes and analyzed by FACS.
  • the fusion polypeptide prepared in Example 2 was injected into a cancer transplant animal model to confirm the effect in vivo.
  • mice Six-week-old female NSG (NOD.Cg-PrkdcscidIl2rgtm1wjl / SzJ) mice were used for in vivo experiments. Mouse management was performed according to the Animal Care Committee of the Laboratory Animal Resource Center of the Korea Research Institute of Bioscience and Biotechnology. Panc-1 was injected into the mouse pancreas to form tumors for 2 weeks, and mesothelin, PD-L1 or Her2 scFV fusion polypeptide (5 mg / kg) was injected intraperitoneally at 5 day intervals.
  • Natural killer cells were injected IV at 1 ⁇ 10 7 / mouse for tumor growth experiments. Tumor growth was observed using Panax-1 expressing luciferase using IVIS Living Image 3.0 program, and motility experiments of natural killer cells were performed using 1 ⁇ 10 7 / mouse of natural killer cells stained with DiR. Dosing was observed by IVIS flourescence Image program and FACS.
  • FIGS. 26 to 29 show the induction of natural killer cells to cancer tissues according to the administration of the fusion polypeptide and natural killer cells prepared in Example 2
  • Figure 27 is mesothelin scFV NRP-body
  • Figure 28 is PD-L1 scFV NRP -body
  • Figure 29 shows the result of confirming the therapeutic effect by administering Her2 scFV NRP-body with natural killer cells.
  • the fusion polypeptide of the present invention showed a significant effect on cancer treatment by enhancing the influx of natural killer cells, which are immune cell therapeutics.
  • IL-2 and CXCL16 which promote the growth of natural killer cells, are used together at concentrations of 200 U and 100 nM, respectively 0, 1, 2, 8 or 16 hours of processing and CD56 dim
  • concentrations of 200 U and 100 nM respectively 0, 1, 2, 8 or 16 hours of processing and CD56 dim
  • CD56 dim the distribution of CD56 bright was confirmed by FACS and the results are shown in Figure 30, the cells in the upper right corner represents the CD56 bright cells.
  • CXCL16 affects the characteristics of natural killer cells by changing CD56 dim to CD56 bright , which has a great effect of ADCC (Antibody dependent cellular cytotoxicity).
  • ADCC Antibody Dependent Cellular Cytotoxicity
  • Panc-1 cell lines were dispensed into 96-well plates and incubated for 2 hours at 37 ° C. in a CO 2 incubator. Natural killer cells were added as 2 x 10 5 so that the ratio of the target cell and the effector cell was 1: 1, and the cells were incubated for 4 hours at 37 °C, CO 2 incubator. The cells were recovered, washed with PBS, stained with Annexin V (1 ⁇ g / ml) and PI (1 ⁇ g / ml) for 30 minutes, and analyzed by FACS.
  • CD56 bright increased by CXCL16 of the fusion polypeptide It was confirmed that cancer cell death was increased by CD16 + natural killer cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une protéine de fusion pour le traitement du cancer, et ses utilisations. La protéine de fusion pour la prévention ou le traitement du cancer selon la présente invention comprend : un anticorps ou un fragment de celui-ci qui se lie à un antigène associé à une tumeur ; une séquence de liaison ; et un polypeptide de fusion comprenant une protéine CXCL16 inductrice des cellules tueuses naturelles. Par conséquent, lorsqu'elle est co-administrée avec une cellule tueuse naturelle, qui est un agent thérapeutique immunocytaire, la protéine de fusion renforce fortement l'introduction de la cellule tueuse naturelle dans une tumeur exprimant un antigène spécifique, et présente ainsi un effet remarquable en matière de prévention ou de traitement du cancer.
PCT/KR2018/004043 2017-04-05 2018-04-05 Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant WO2018186706A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2019554653A JP6933724B2 (ja) 2017-04-05 2018-04-05 Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物
US16/500,051 US11655306B2 (en) 2017-04-05 2018-04-05 NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
RU2019135054A RU2740438C1 (ru) 2017-04-05 2018-04-05 Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их
IL269801A IL269801B2 (en) 2017-04-05 2018-04-05 A fusion protein that activates NK cells, an NK cell, and a pharmaceutical preparation that includes them
CA3057989A CA3057989C (fr) 2017-04-05 2018-04-05 Proteine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant
CN201880025476.7A CN110573529A (zh) 2017-04-05 2018-04-05 激活nk细胞的融合蛋白、nk细胞和包含其的药物组合物
MX2019011958A MX2019011958A (es) 2017-04-05 2018-04-05 Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.
AU2018248672A AU2018248672B2 (en) 2017-04-05 2018-04-05 NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
BR112019020909-3A BR112019020909A2 (pt) 2017-04-05 2018-04-05 Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma
EP18781754.9A EP3594242A4 (fr) 2017-04-05 2018-04-05 Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170043988 2017-04-05
KR10-2017-0043988 2017-04-05

Publications (1)

Publication Number Publication Date
WO2018186706A1 true WO2018186706A1 (fr) 2018-10-11

Family

ID=63712339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004043 WO2018186706A1 (fr) 2017-04-05 2018-04-05 Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant

Country Status (12)

Country Link
US (1) US11655306B2 (fr)
EP (1) EP3594242A4 (fr)
JP (1) JP6933724B2 (fr)
KR (1) KR102009040B1 (fr)
CN (1) CN110573529A (fr)
AU (1) AU2018248672B2 (fr)
BR (1) BR112019020909A2 (fr)
CA (1) CA3057989C (fr)
IL (1) IL269801B2 (fr)
MX (1) MX2019011958A (fr)
RU (1) RU2740438C1 (fr)
WO (1) WO2018186706A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114887080B (zh) * 2020-12-08 2023-10-31 深圳瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
CN114588258B (zh) * 2022-05-10 2023-04-25 中山大学 Bmp9联合nk细胞和pd-l1抗体在制备肝癌药物方面的应用
CN116790616B (zh) * 2023-07-07 2023-12-15 佛山科学技术学院 编码sCXCL16的基因及表达载体、制备方法和应用
WO2025033876A1 (fr) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 Conjugué protéine de fusion modifiée-scfv et son utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
US20100183516A1 (en) * 2007-07-25 2010-07-22 Markus Ribbert Self coupling recombinant antibody fusion proteins
WO2014043523A1 (fr) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
KR20150063145A (ko) 2012-10-02 2015-06-08 메모리얼 슬로안-케터링 캔서 센터 면역치료용 조성물 및 방법
WO2016176756A1 (fr) * 2015-05-05 2016-11-10 University Health Network Cellules tueuses naturelles et anticorps pour le traitement du cancer
KR101732126B1 (ko) * 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1945674A2 (fr) * 2005-11-03 2008-07-23 Genentech, Inc. Polypeptides thérapeutiques de fusion d'anticorps anti-her2
KR20090053222A (ko) * 2007-11-22 2009-05-27 한국생명공학연구원 체액 내 대장암 마커로서의 ｃｘｃｌ－１６유전자 및 이를이용한 대장암의 진단 및 치료에의 용도
EP2262531A1 (fr) * 2008-03-08 2010-12-22 Immungene, Inc. Immunothérapie avec molécules de fusion modifiées utilisées dans le cancer et les maladies inflammatoires
WO2011025962A1 (fr) * 2009-08-28 2011-03-03 Dan Allison Anticorps antikines se liant à plusieurs chimiokines cc
US9249204B2 (en) * 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
JP6487328B2 (ja) * 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
CN105518143B (zh) * 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
KR102627811B1 (ko) * 2015-06-10 2024-01-24 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
US11723922B2 (en) * 2015-10-16 2023-08-15 Ludwig-Maximilians-Universität München CXCR6-transduced T cells for targeted tumor therapy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
US20100183516A1 (en) * 2007-07-25 2010-07-22 Markus Ribbert Self coupling recombinant antibody fusion proteins
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
WO2014043523A1 (fr) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
KR20150063145A (ko) 2012-10-02 2015-06-08 메모리얼 슬로안-케터링 캔서 센터 면역치료용 조성물 및 방법
WO2016176756A1 (fr) * 2015-05-05 2016-11-10 University Health Network Cellules tueuses naturelles et anticorps pour le traitement du cancer
KR101732126B1 (ko) * 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2005, UNIVERSITY OF THE SCIENCES IN PHILADELPHIA
HESS, CHRISTIAN ET AL.: "Evaluation of Antibody-chemokine Fusion Proteins for Tumor-targeting Applications", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 239, no. 7, 2014, pages 842 - 852, XP002783565, Retrieved from the Internet <URL:https://doi.org/10.1177/1535370214536667> *

Also Published As

Publication number Publication date
IL269801A (fr) 2020-02-27
JP6933724B2 (ja) 2021-09-08
KR20180113183A (ko) 2018-10-15
CN110573529A (zh) 2019-12-13
RU2740438C1 (ru) 2021-01-14
EP3594242A1 (fr) 2020-01-15
IL269801B2 (en) 2024-02-01
EP3594242A4 (fr) 2020-12-09
CA3057989A1 (fr) 2018-10-11
MX2019011958A (es) 2019-12-11
KR102009040B1 (ko) 2019-08-08
BR112019020909A2 (pt) 2020-05-12
CA3057989C (fr) 2023-03-21
US11655306B2 (en) 2023-05-23
IL269801B1 (en) 2023-10-01
AU2018248672A1 (en) 2019-11-14
AU2018248672B2 (en) 2021-09-30
JP2020515624A (ja) 2020-05-28
US20200148786A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2019229076B2 (en) Anti-TIGIT antibodies and uses thereof
KR102309950B1 (ko) 체크포인트 억제제 이중특이적 항체
WO2018186706A1 (fr) Protéine de fusion activant les cellules nk, cellule nk et composition pharmaceutique en comprenant
WO2018222019A1 (fr) Nouveaux anticorps anti-cd40 et leur utilisation
WO2020153605A1 (fr) Récepteur antigénique chimérique spécifique de la mésothéline et lymphocytes t l&#39;exprimant
WO2021091359A1 (fr) Épitope d&#39;antigène de surface de lymphocyte t régulateur, et anticorps se liant de manière spécifique à celui-ci
WO2017030370A1 (fr) Récepteur d&#39;anticorps chimérique auquel est lié un anticorps anti-cotinine et utilisation de celui-ci
CA3191454A1 (fr) Proteine de fusion comprenant il-12 et anticorps anti-fap et utilisation associee
AU2018237024B2 (en) Anti-CEACAM1 antibody and use thereof
WO2021210939A1 (fr) Afficorps anti-her2 et récepteur antigénique chimérique commutable utilisant celui-ci en tant que molécule de commutation
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
US20240400640A1 (en) Fusion protein dimer including pd-1 and il-21, and use thereof
WO2021158091A2 (fr) Composition comprenant un inhibiteur de chimiokine, un inhibiteur de facteur de stimulation de colonie et un agent d&#39;immunothérapie anticancéreuse pour la prévention ou le traitement du cancer et la polythérapie
WO2022169269A1 (fr) Anticorps anti-ctla-4 et son utilisation
WO2019216675A1 (fr) Épitope d&#39;antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
WO2021153979A1 (fr) Protéine de fusion comprenant un anticorps anti-taa, un anticorps anti-pd-l1 et il-2 et les utilisations correspondantes
WO2023022271A1 (fr) Anticorps anti-igsf1 et son utilisation
WO2024049161A1 (fr) Nouveau récepteur antigénique chimérique anti-pd-l1 et cellules immunitaires l&#39;exprimant
JP2024534838A (ja) ＮＫｐ４６結合ポリペプチド及びその使用
WO2021172690A1 (fr) Récepteur antigénique chimérique spécifique de la mésothéline et ses utilisations
WO2024191168A1 (fr) Nouvel anticorps se liant à cd3 et anticorps multispécifique le comprenant
WO2018124851A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, contenant un anticorps se liant spécifiquement à une protéine l1cam et un analogue de la pyrimidine et/ou un médicament anticancéreux à base de platine
WO2021034098A1 (fr) Utilisation d&#39;immunocytokine comprenant l&#39;interféron-bêta ou un variant de celui-ci pour le traitement d&#39;un cancer positif pour le récepteur 2 du facteur de croissance épidermique humain
EP4477228A1 (fr) Composition pharmaceutique pour le traitement du cancer comprenant une protéine de fusion comprenant il-12 et un anticorps anti-fap et un agent anticancéreux
WO2024172363A1 (fr) Anticorps anti-cntn4 et ses utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18781754

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3057989

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019554653

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019020909

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018781754

Country of ref document: EP

Effective date: 20191011

ENP Entry into the national phase

Ref document number: 2018248672

Country of ref document: AU

Date of ref document: 20180405

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019020909

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191004

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载